ALMIRALL, S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.16 EUR | +1.05% |
|
+5.47% | +8.72% |
| Mar. 13 | Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment | MT |
| Feb. 19 | Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB... |  |
Presentation Operator MessageOperator (Operator)Good day, and welcome to the Almirall Full Yea...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
9.16
EUR
Average target price
11.21
EUR
Spread / Average Target
+22.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.72% | 2.07B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- ALM Stock
- News Almirall, S.A.
- Transcript : Almirall, S.A., 2021 Earnings Call, Feb 21, 2022
